Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical

Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.

from Moneycontrol Business News https://ift.tt/rucI6iB